Six weeks of daily rifapentine vs. a comparator arm of 12-16 week rifamycin-based treatment of latent M. tuberculosis infection: assessment of safety, tolerability and effectiveness - ASTERoiD
Lay Description
Category
- Immune System
- Infections / Infectious Diseases
- IRB Number
- 20180194HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Jose Cadena Zuluaga
(210) 567-4666
cadenazuluag@uthscsa.edu
Melissa Engle
(210) 617-5300
englem2@uthscsa.edu
Melissa Engle
(210) 617-5300
englem2@uthscsa.edu
Jose Cadena Zuluaga
(210) 567-4666
cadenazuluag@uthscsa.edu
Principal Investigator
Jose Cadena Zuluaga